Eagle Pharmaceuticals Inc. (EGRX)

56.73
NASDAQ : Health Technology
Prev Close 58.68
Day Low/High 55.90 / 59.56
52 Wk Low/High 36.03 / 70.13
Avg Volume 141.20K
Exchange NASDAQ
Shares Outstanding 14.86M
Market Cap 872.10M
EPS 2.20
P/E Ratio 20.68
Div & Yield N.A. (N.A)
Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three- and nine-months ended September 30, 2016.

3 Small-Caps Bucking the Downtrend

3 Small-Caps Bucking the Downtrend

News announcements from these companies are supportive of continued strength.

3 Small-Caps Bucking the Downtrend

3 Small-Caps Bucking the Downtrend

News announcements from these companies is supportive of continued strength.

CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection

CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Eagle Pharmaceuticals, Inc.

Final Reminder: Eagle Pharmaceuticals To Host 2016 Investor Day In New York City

Final Reminder: Eagle Pharmaceuticals To Host 2016 Investor Day In New York City

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) today issued a final reminder regarding its previously announced 2016 Investor Day.

RSI Alert: Eagle Pharmaceuticals Now Oversold

RSI Alert: Eagle Pharmaceuticals Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eagle Pharmaceuticals Announces Positive Initial Results Of Animal Study Exploring Use Of Ryanodex In MDMA (Ecstasy) Induced Hyperthermia Conducted At The National Institutes Of Health

Eagle Pharmaceuticals Announces Positive Initial Results Of Animal Study Exploring Use Of Ryanodex In MDMA (Ecstasy) Induced Hyperthermia Conducted At The National Institutes Of Health

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced initial results from the preclinical study conducted by Eagle at the National Institute on Drug Abuse ("NIDA")/National Institutes of...

Eagle Pharmaceuticals, Inc. To Discuss Third Quarter 2016 Financial Results On November 9, 2016

Eagle Pharmaceuticals, Inc. To Discuss Third Quarter 2016 Financial Results On November 9, 2016

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) announced today that the Company will release its 2016 third quarter financial results on Wednesday, November 9, 2016, before the market opens.

Eagle Pharmaceuticals Announces "Save The Date" For 2016 Investor Day

Eagle Pharmaceuticals Announces "Save The Date" For 2016 Investor Day

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, David Riggs, Chief Financial Officer, and other members of Eagle's senior...

How to Play It When the FDA Slams Your Stock

How to Play It When the FDA Slams Your Stock

Here are three recent examples of how the patient can profit.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ACM, ACTS, BID, CC, COH, COKE, DSCI, EGRX, FNV, NWS, SHO, SSNC Downgrades: AMBC, HHC, HLF, LXFR, ROG, TCP Initiations: APLE, CNXR, EKSO, GNL, HLTH, LIND Read on to get TheStreet Quant Ratings' detailed report:

Shark Bites: Join the Momentum Parade

Shark Bites: Join the Momentum Parade

The benefits of following the big movers.

Eagle Pharmaceuticals (EGRX) Strong On High Relative Volume Today

Eagle Pharmaceuticals (EGRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a strong on high relative volume candidate

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three- and six-months ended June 30, 2016.

Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission

Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission

Eagle Pharmaceuticals ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the U.

These 5 Stocks Are Set to Soar on Bullish Earnings

These 5 Stocks Are Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Eagle Pharmaceuticals (EGRX) Showing Signs Of Perilous Reversal Today

Eagle Pharmaceuticals (EGRX) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a "perilous reversal" (up big yesterday but down big today) candidate

August 1 Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Eagle Pharmaceuticals Inc.

August 1 Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Eagle Pharmaceuticals Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  August 1, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased...

Commit To Purchase Eagle Pharmaceuticals At $35, Earn 14.7% Annualized Using Options

Commit To Purchase Eagle Pharmaceuticals At $35, Earn 14.7% Annualized Using Options

Investors eyeing a purchase of Eagle Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $45.38/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Eagle Pharmaceuticals, Inc. To Discuss Second Quarter 2016 Financial Results On August 9, 2016

Eagle Pharmaceuticals, Inc. To Discuss Second Quarter 2016 Financial Results On August 9, 2016

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) announced today that the Company will release its 2016 second quarter financial results on Tuesday, August 9, 2016, before the market opens.

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Eagle Pharmaceuticals Inc. Investors And Encourages Investors To Contact The Firm

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Eagle Pharmaceuticals Inc. Investors And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Eagle Pharmaceuticals Inc.

Trade-Ideas: Eagle Pharmaceuticals (EGRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Eagle Pharmaceuticals (EGRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. And Reminds Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. And Reminds Investors With Losses To Contact The Firm

Lundin Law PC announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Eagle Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of August 1, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Eagle Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of August 1, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals, Inc.

A Mid-Year Look at 4 Best Ideas Picks

A Mid-Year Look at 4 Best Ideas Picks

I still like and own these small-caps.

INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Lawsuit Involving Eagle Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of August 1, 2016

INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Lawsuit Involving Eagle Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of August 1, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc.

DEADLINE ALERT - EAGLE PHARMACEUTICALS, INC. - Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 To Contact The Firm

DEADLINE ALERT - EAGLE PHARMACEUTICALS, INC. - Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Eagle Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of August 1, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Eagle Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of August 1, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Announces Changes To Its Board Of Directors; Director, Michael Graves Appointed Chairman

Eagle Pharmaceuticals Announces Changes To Its Board Of Directors; Director, Michael Graves Appointed Chairman

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") today announced that Douglas L.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Eagle Pharmaceuticals Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Eagle Pharmaceuticals Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Eagle Pharmaceuticals Inc.

TheStreet Quant Rating: B- (Buy)